Diversionary Therapy Technologies Pty Ltd (DTT) was established as a joint venture
between the Australasian Cooperative Research Centre for Interaction Design (ACID) and local
investors to commercialise a new diversionary therapy device that significantly reduces pain
scores during wound-dressing changes, which can be a lengthy and excruciating procedure for
patients and their carers.
ACID sold its shareholding in DTT in 2008. Since then, DTT has continued chemical trials and development, moving towards commercial release on a global scale.